Alumis Inc.
ALMS
Rank in Stocks
#10157
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Share Price
$6.41
Last synced: 2026-10-19
Market Cap
$830.25M
Change (1 day)
4.81%
Change (1 year)
182.57%
Country
US
Trade Alumis Inc. (ALMS)
Category
Healthcare
Number of shares outstanding for Alumis Inc. (ALMS)
Number of shares outstanding as of March 2025: 100.68M
According to Alumis Inc. latest financial reports and stock price the company's current number of shares outstanding is 100.68M. At the end of December 2023 the company had 70.25M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Alumis Inc. (ALMS) from 2021 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 100.68M | 1.39% |
| 2024 | 99.30M | 41.35% |
| 2023 | 70.25M | 243.63% |
| 2022 | 20.44M | 0.00% |
| 2021 | 20.44M | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.90M | 152.18% |
US
|
|
| 396.00M | 293.32% |
US
|
|
| 478.91M | 375.68% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -38.23% |
NL
|
